CLARKSVILLE, MD--(Marketwired - Jun 25, 2013) - Neuronascent, Inc. announced today the issuance of a Canadian patent covering its compound families that include Neuronascent's Alzheimer's therapy, NNI-362, and other agents that promote neurogenesis to treat both neuropsychiatric and neurodegenerative disorders. The Company's patent portfolio covering these agents also includes coverage in the United States, Russia and South Korea.
"Neuronascent strives to be the leader in the neuro-restorative therapeutic approach to Alzheimer's disease," said Judith Kelleher-Andersson, Ph.D., Founder, President and Chief Scientific Officer of Neuronascent. "With 5.4 million Americans suffering from Alzheimer's and no disease-modifying therapy on the horizon, our therapeutic development efforts focus directly on replacing neurons in an aging patient population with chronic neuronal loss." Kelleher-Andersson continued, "Our multi-targeted agent is both neurogenic and neuroprotective and is aimed at reversing or halting the disease, not merely minimizing further neuronal loss."
NNI-362 has been validated through oral administration in external studies, which indicated a reversal of memory impairment in aged mice and the promotion of new neuron growth from the brain's own neuronal progenitors, similar to that observed in young mice. NNI-362 also promoted contextual memory benefit in Down syndrome mice, correlating with an increase in the number of neurons to levels observed in normal mice.
Neuronascent, Inc. is a pre-IND stage company developing orally available, novel neurogenic and neuro-restorative therapeutics that target Alzheimer's disease, Down syndrome, Parkinson's disease and post-traumatic stress disorder.
Safe Harbor Statement
This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations.